-
公开(公告)号：US09139587B2
公开(公告)日：2015-09-22
申请号：US14273912
申请日：2014-05-09
Applicant: Pfizer Inc.
Inventor： Scott William Bagley , David Andrew Griffith , Daniel Wei-Shung Kung
IPC: C07D471/10 , C07D519/00
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
公开(公告)号：US08802690B2
公开(公告)日：2014-08-12
申请号：US13939450
申请日：2013-07-11
Applicant: Pfizer Inc.
Inventor： Scott William Bagley , David Andrew Griffith , Daniel Wei-Shung Kung
IPC: C07D487/10 , A61K31/438
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
公开(公告)号：US11708360B2
公开(公告)日：2023-07-25
申请号：US17192968
申请日：2021-03-05
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
CPC classification number: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)
or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.-
公开(公告)号：US09399626B2
公开(公告)日：2016-07-26
申请号：US14299497
申请日：2014-06-09
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K31/513 , A61K31/352 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/10 , C07D487/04 , C07D417/04 , C07D471/04 , A61K31/37
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Abstract translation: 髓过氧化物酶抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于治疗例如心血管病症的用途。
-
公开(公告)号：US09394285B2
公开(公告)日：2016-07-19
申请号：US14773954
申请日：2013-09-24
Applicant: Pfizer Inc.
Inventor： Samit Kumar Bhattacharya , Kimberly O'Keefe Cameron , Matthew Scott Dowling , David Christopher Ebner , David James Edmonds , Dilinie Prasadhini Fernando , Kevin James Filipski , Daniel Wei-Shung Kung , Esther Cheng Yin Lee , Aaron Christopher Smith , Meihua Mike Tu
IPC: C07D405/12 , C07D403/12 , C07D401/04 , C07D401/12 , A61K31/404 , A61K31/4439 , A61K31/454 , A61K31/496 , A61P13/12 , A61P3/10
CPC classification number: C07D405/12 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D403/12
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。
-
Patent Agency Ranking
公开(公告)号：US20130296351A1
公开(公告)日：2013-11-07
申请号：US13875604
申请日：2013-05-02
Applicant: Pfizer Inc.
Inventor： Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K45/06 , A61K31/513
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
Abstract translation: 髓过氧化物酶抑制剂，含有这些抑制剂的药物组合物以及这些抑制剂用于治疗例如心血管病症的用途。
-
17.发明申请公开(公告)号：US20130030181A1
公开(公告)日：2013-01-31
申请号：US13644415
申请日：2012-10-04
Applicant: Pfizer Inc.
Inventor： Scott William Bagley , David Andrew Griffith , Daniel Wei-Shung Kung
IPC: C07D471/10
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。
-
公开(公告)号：US20250129048A1
公开(公告)日：2025-04-24
申请号：US18713747
申请日：2022-12-05
Applicant: Pfizer Inc.
Inventor： Michelle Renee Garnsey , David Andrew Griffith , Christopher John Helal , Daniel Wei-Shung Kung , Yajing Lian , Kevin Alexander Ogilvie , Jana Polivkova , Brian Raymer , Matthew Forrest Sammons , Aaron Christopher Smith , Qingyi Yang
IPC: C07D401/14 , A61K31/4439 , A61K31/444 , A61K31/506 , C07D413/14 , C07D471/04 , C07D498/04
Abstract: Described herein are compounds of Formula I: I and their pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R7, RF, t1, Y1, and Y2 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
-
公开(公告)号：US20240368144A1
公开(公告)日：2024-11-07
申请号：US18311266
申请日：2023-05-03
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
公开(公告)号：US20210206757A1
公开(公告)日：2021-07-08
申请号：US17192968
申请日：2021-03-05
Applicant: Pfizer Inc.
Inventor： Brian Stephen Gerstenberger , Andrew Christopher Flick , Daniel Wei-Shung Kung , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Daniel Copley Schmitt , Mark Edward Schnute , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.035 seconds)
